Testosterone Propionate
Test P
Testosterone propionate ("Test P") is injectable testosterone — the body's principal endogenous androgen — chemically joined to a short propionic-acid ester so it can be given as an intramuscular oil depot. Medically it is used for testosterone-replacement in male hypogonadism; outside medicine it is used at supraphysiologic doses to build muscle and strength. The propionate ester is short-acting, so it is injected frequently. It is the same testosterone molecule as other esters; the ester only changes release speed, not the risk profile. The main risks, most severe at the supraphysiologic doses typical of non-medical use, are that it raises red-cell mass (higher hematocrit) which increases clotting/stroke/heart-attack risk; it is associated with reduced heart pumping and relaxation function and accelerated coronary plaque; it lowers protective HDL cholesterol and raises blood pressure; it aromatizes to estradiol (which can drive gynecomastia); it shuts down the body's own testosterone production and sperm output, sometimes for a prolonged or occasionally permanent period after stopping; and in a minority of users it triggers irritability, aggression, or hypomania, with depression on withdrawal. It is educational information only, not medical advice; these risks warrant physician supervision and regular bloodwork, and it is inappropriate for anyone under 21.
Mechanism of action
Pharmacokinetics
Short. The propionate is the shortest-chain of the common testosterone esters and confers a short duration of action on the order of roughly 2-3 days after intramuscular injection; unesterified testosterone released from it has a very short intrinsic half-life. Dedicated human pharmacokinetic data specific to testosterone propionate are limited, and depot-release behavior of oily testosterone-ester injections has been characterized largely in animal models.
Approximately 1-3 days; in historical clinical use it required frequent (every 1-3 day) dosing because levels fall quickly after each injection.
Intramuscular injection of an oil-based depot.
The ester is hydrolyzed to testosterone, which undergoes hepatic metabolism, 5α-reduction to DHT, and aromatization to estradiol; metabolites are conjugated and excreted predominantly in urine. This PK is provided for monitoring, washout, and clinician discussion only — not for evading testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Increases lean body mass, thigh-muscle area, and maximal muscle strength in a dose-dependent manner in controlled human trials
- Reduces fat mass; the increase in body fat seen when testosterone/estradiol are low is primarily attributable to estrogen deficiency, reflecting testosterone's aromatization to estradiol
- Maintains libido and secondary sexual characteristics; sexual desire declines as testosterone falls
- At supraphysiologic (non-medical) doses these physique/performance effects are inseparable from a substantial adverse-effect burden across multiple organ systems
Adverse effects by system
Associated with reduced left-ventricular systolic and diastolic function and accelerated coronary atherosclerotic plaque (dose-related to lifetime exposure) in long-term anabolic-steroid users; subclinical systolic dysfunction (reduced global longitudinal strain) and right-ventricular dysfunction persist even during off-cycle periods. Therapeutic-dose testosterone lowers HDL cholesterol and can raise blood pressure. Erythrocytosis adds thrombotic risk. At guideline replacement doses, testosterone therapy (transdermal) was noninferior to placebo for major adverse cardiac events but showed higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the large TRAVERSE RCT — a class-level signal applicable to testosterone itself regardless of ester.
Injectable testosterone esters are not 17α-alkylated and bypass hepatic first-pass, so hepatotoxicity is low relative to oral 17α-alkylated steroids. However, testosterone and its derivatives can, with high or prolonged exposure, cause cholestasis, peliosis hepatis, and benign or malignant hepatic tumors; liver enzyme elevations have been observed with injectable testosterone regimens. Injury usually improves after discontinuation, though some tumor/vascular consequences can be irreversible.
Suppresses hypothalamic-pituitary output (LH and FSH), shutting down endogenous testosterone production; testicular atrophy is expected. Aromatization raises estradiol, which can cause gynecomastia. Withdrawal after long-term use may produce prolonged, and occasionally irreversible, hypogonadism.
Suppresses spermatogenesis; injectable testosterone regimens produce marked sperm-count reduction and azoospermia in most men, with testicular atrophy. Fertility usually recovers after stopping but recovery is variable and can be prolonged. Testosterone is contraindicated in men seeking near-term fertility.
In a randomized controlled trial, supraphysiologic testosterone (up to 600 mg/week) significantly increased manic and aggressive symptoms, but the reaction was idiosyncratic — most men showed minimal change while a minority became hypomanic. Irritability, aggression, and violence during use and depression during withdrawal are reported but affect only a subset of users.
A higher incidence of acute kidney injury was observed in the testosterone group vs placebo in the TRAVERSE RCT, a documented class-level human renal signal for testosterone itself. No adequate human data specific to testosterone propionate beyond this class-level trial exist. Nephrotoxicity has additionally been reported in the broader anabolic-steroid literature and demonstrated in animal models (oxidative injury, focal segmental glomerulosclerosis with nandrolone); secondary renal strain (e.g., from polycythemia/dehydration) is also a concern.
Reliably increases hemoglobin and hematocrit (a small but consistent rise even at therapeutic doses; larger increases, e.g. ~9% hemoglobin and ~15% hematocrit, seen with some injectable regimens). Testosterone use is a recognized cause of secondary erythrocytosis; marked elevations raise the risk of venous and arterial thrombosis and warrant intervention such as dose reduction or phlebotomy.
Acne and oily skin are recognized androgen-mediated effects, and male-pattern hair loss can be accelerated in genetically predisposed men. Dedicated high-quality trial data quantifying these skin effects for testosterone propionate specifically are limited; they are extrapolated from the general androgen/anabolic-steroid literature.
HPTA suppression & recovery
Suppression: Marked/profound. Exogenous testosterone suppresses LH and FSH, halting endogenous testosterone production and spermatogenesis, with expected testicular atrophy.
Recovery of the hypothalamic-pituitary-gonadal axis after stopping is variable and individual; after long-term use it may be prolonged and is occasionally irreversible. Any recovery strategy should be directed by an endocrinologist. Only single-SERM approaches are within scope here; dual-SERM protocols are not described or recommended. This content is conservative and defers to specialist medical management.
Monitoring
Cadence: Baseline before any use, then periodic re-evaluation (for example within the first 3-6 months and at least annually thereafter), with prostate and hematocrit assessment emphasized in the first year, consistent with endocrine-society monitoring frameworks. All monitoring should be arranged with a physician.
- Chest pain, shortness of breath, or exertional intolerance
- Leg swelling, pain, or redness suggesting deep-vein thrombosis; sudden severe headache, facial/limb weakness, or vision change suggesting stroke
- Hematocrit rising toward or above ~54%
- Yellowing of skin/eyes, dark urine, or right-upper-quadrant abdominal pain (possible liver injury)
- New or worsening aggression, mania, or suicidal thoughts; depression on withdrawal
- Breast tenderness or enlargement (gynecomastia)
Contraindications
- Known or suspected prostate cancer or breast cancer in men
- Palpable prostate nodule/induration or elevated PSA without prior urological evaluation
- Elevated hematocrit/polycythemia at baseline
- Untreated severe obstructive sleep apnea
- Severe lower urinary tract symptoms
- Uncontrolled or poorly controlled heart failure
- Myocardial infarction or stroke within the preceding 6 months
- Thrombophilia or high thrombotic risk
- Men desiring fertility in the near term (suppresses spermatogenesis)
- Pregnancy/possible pregnancy (androgens are teratogenic to a female fetus); not appropriate for women or adolescents outside specialist care
Interaction profile
- MajorWith another anabolic steroid: Additive cardiovascular strain
- MajorWith a thermogenic stimulant: Additive cardiovascular strain
- ModerateWith thyroid hormone: Additive cardiovascular strain
- ModerateWith growth hormone: Additive cardiovascular strain
- MajorWith another anabolic steroid: Blood / clotting
- MajorWith a clot-promoting SERM: Blood / clotting
- ModerateWith an aromatase inhibitor: Hormonal
- ModerateWith an anabolic steroid: Hormonal
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- This is educational information only and not medical advice; these substances carry serious risks and use should occur under a qualified physician with regular bloodwork. Not appropriate for anyone under 21.
- Obtain baseline labs (hematocrit, lipids, liver function, PSA where age-appropriate, testosterone/estradiol, blood pressure) before any use and monitor periodically with a clinician.
- Rising hematocrit (approaching or above ~54%) increases clot, stroke, and heart-attack risk; discuss dose reduction or therapeutic phlebotomy with a physician and seek care for symptoms of thrombosis.
- Stop and seek urgent medical care for chest pain, breathlessness, signs of DVT/stroke, jaundice or severe abdominal pain, or a mental-health crisis (severe aggression, mania, or suicidal thoughts).
- Recovery of natural testosterone and fertility after stopping is variable and can be prolonged or occasionally permanent; any recovery plan should be directed by an endocrinologist, and only single-SERM approaches are within scope (dual-SERM protocols are not).
- Absence of data (e.g., for testosterone-propionate-specific renal risk) is not evidence of safety; women, adolescents, and anyone planning fertility face particular harm.
Citations (17)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Testosterone increases lean body mass, muscle size, and strength; androgen deficiency accounts for losses in lean mass/strength while estrogen deficiency (from reduced aromatization) primarily drives increased body fat, and sexual desire declines as testosterone falls.
RCTGonadal steroids and body composition, strength, and sexual function in menPMID 24024838 ↗
- 02
Testosterone aromatizes to estradiol, and estradiol mediates the body-fat effects of testosterone in men.
RCTGonadal steroids and body composition, strength, and sexual function in menPMID 24024838 ↗
- 03
Supplemental testosterone produces dose-dependent gains in lean mass and strength but also raises systolic and diastolic blood pressure.
RCTTestosterone and growth hormone improve body composition and muscle performance in older men.PMID 19293261 ↗
- 04
Testosterone therapy significantly increases hemoglobin and hematocrit and decreases HDL cholesterol, with no significant effect on mortality, prostate, or cardiovascular outcomes in short/therapeutic-dose trials of generally low quality.
Meta-analysisClinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysisPMID 20525906 ↗
- 05
Long-term anabolic-androgenic steroid use is associated with reduced left-ventricular systolic and diastolic function and accelerated coronary atherosclerosis, with coronary plaque burden associated with cumulative lifetime dose.
CohortCardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid UsePMID 28533317 ↗
- 06
Subclinical left-ventricular systolic dysfunction (reduced global longitudinal strain) persists in anabolic-steroid users even during off-cycle abstinence.
CohortChronic anabolic androgenic steroid administration reduces global longitudinal strain among off-cycle bodybuilders.PMID 37003371 ↗
- 07
Right-ventricular systolic function (free-wall strain) is reduced in long-term anabolic-steroid-using bodybuilders versus non-users.
CohortComparison of Right Ventricle Systolic Function between Long-Term Anabolic-Androgenic Steroid User and Nonuser Bodybuilder Athletes: A Study of Two-Dimensional Speckle Tracking Echocardiography.PMID 27144714 ↗
- 08
Supraphysiologic testosterone (up to 600 mg/week) significantly increased manic and aggressive symptoms in a randomized controlled trial, but the effect was idiosyncratic, with most men showing minimal change and a minority becoming hypomanic.
RCTEffects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial.PMID 10665615 ↗
- 09
Withdrawal from androgens after long-term use may produce prolonged and sometimes irreversible hypogonadism; supraphysiologic androgen use is linked to cardiomyopathy, atherosclerosis, hepatotoxicity, nephrotoxicity, and idiosyncratic psychiatric effects (aggression during use, depression on withdrawal).
ReviewPublic health impact of androgens.PMID 29369918 ↗
- 10
Injectable testosterone regimens suppress LH and FSH and spermatogenesis (azoospermia in most men) and increase hemoglobin (~9%) and hematocrit (~15%), with observed liver-enzyme elevations.
CohortInvestigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants.PMID 12443967 ↗
- 11
Testosterone use is a recognized cause of secondary erythrocytosis; elevated hematocrit carries thrombotic risk and is managed by measures such as phlebotomy to a hematocrit below 45%.
ReviewPolycythemia Vera: Rapid Evidence Review.PMID 34060791 ↗
- 12
Testosterone and its derivatives can cause cholestasis, peliosis hepatis, and benign/malignant hepatic tumors, generally with supraphysiologic prolonged exposure; injury usually normalizes after discontinuation though some consequences are irreversible.
ReviewAnabolic androgenic steroid-induced liver injury: An update.PMID 36051334 ↗
- 13
Anabolic-androgenic steroid hepatotoxicity includes adenoma, hepatocellular carcinoma, cholestasis, and peliosis hepatis.
ReviewHepatotoxicity associated with illicit use of anabolic androgenic steroids in doping.PMID 28379599 ↗
- 14
Oily intramuscular testosterone-ester injections form a depot with delayed release; the propionate ester behavior and depot dynamics have been characterized in animal (rat) models.
PreclinicalInfluence of solvent on the availability of testosterone propionate from oily, intramuscular injections in the rat.PMID 2882010 ↗
- 15
Chronic nandrolone (an anabolic steroid) administration induces oxidative renal injury and focal segmental glomerulosclerosis in animal models; human renal data specific to testosterone are lacking.
PreclinicalChronic nandrolone administration promotes oxidative stress, induction of pro-inflammatory cytokine and TNF-alpha mediated apoptosis in the kidneys of CD1 treated mice.PMID 25065671 ↗
- 16
Testosterone therapy contraindications and monitoring: avoid in prostate/breast cancer, prostate nodule or PSA elevation without workup, elevated hematocrit, untreated severe OSA, severe LUTS, uncontrolled heart failure, recent (within 6 months) MI/stroke, thrombophilia, or near-term fertility plans; monitor testosterone, hematocrit, and prostate, especially in the first year.
GuidelineTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.PMID 29562364 ↗
- 17
In middle-aged/older hypogonadal men with high cardiovascular risk, guideline-dose transdermal testosterone therapy was noninferior to placebo for major adverse cardiac events but showed higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury.
RCTCardiovascular Safety of Testosterone-Replacement Therapy.PMID 37326322 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice